Murphy & Mullick Capital Management’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Murphy & Mullick Capital Management’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.6K	Hold	115	–	–	0.01%	459
2026 Q1	$11.9K	Hold	115	–	–	0.01%	453
2025 Q4	$12K	Hold	115	–	–	0.01%	459
2025 Q3	$11K	Hold	115	–	–	0.01%	458
2025 Q2	$9.19K	Hold	115	–	–	0.01%	471
2025 Q1	$9.96K	Hold	115	–	–	0.01%	446
2024 Q4	$9.5K	Buy	+115	New	+$9.89K	0.01%	445

Other funds holding PJP

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

JGCM

Joseph Group Capital Management Columbus, Ohio $476M AUM 21.21% 1-Year Est. Return

Murphy & Mullick Capital Management's PJP Position: Q2 2026 in Review

Murphy & Mullick Capital Management held its Invesco Pharmaceuticals ETF (PJP) position steady in Q2 2026 at 115 shares worth $13.6K. The position accounts for 0.01% of the portfolio, ranked #459.

Murphy & Mullick Capital Management first reported a position in PJP in Q4 2024 and has held it in 7 quarters since. 117 funds tracked by Wall St. Rank hold PJP as of Q2 2026.

Murphy & Mullick Capital Management held 115 shares of Invesco Pharmaceuticals ETF worth $13.6K as of Q2 2026.
Murphy & Mullick Capital Management left its Invesco Pharmaceuticals ETF share count unchanged in Q2 2026.
Invesco Pharmaceuticals ETF made up 0.01% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #459 holding.
Murphy & Mullick Capital Management first reported a position in Invesco Pharmaceuticals ETF in Q4 2024 and has held it in 7 quarters since.
117 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.